DUAL study extension 2nd season: Benefit of Omalizumab and SIT over SIT alone maintained for GETE evaluation but not for symptom load

Background: Previous study data generated in patients with grass- and rye pollen seasonal allergic asthma in 2006 have demonstrated a statistically significant and clinically relevant superiority of the combination of Xolair® (Omalizumab, OMA) plus a depigmented allergenic extract (Depigoid®) versus SIT monotherapy. There are now data available on the follow-up season in 2007 in which both arms have been treated with SIT only after the core study in 2006 was finished. The purpose of this extension study was to assess the possible long-term effects of a single pre- and co-seasonal treatment period with OMA+SIT ve…